We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Researchers Will Have Ready Access to Molecular Diagnostics Expertise at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 30 Jul 2013
Biotech and other life science researchers will be able to consult with a team of molecular diagnostics (MDx) experts at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

The New England Biolabs (Ipswich, MA, USA) NEBsolutions team of experts will be available at booth 4463 during the Lab Expo meeting. More...
The team is in place to direct access to expertise in enzymology, supply logistics, custom formulations, packaging, and kit development and to maximize access to New England Biolabs' catalogue of high-quality reagents. New England Biolabs provides reagents for a variety of MDx applications, such as sample preparation, PCR, RT-PCR, isothermal amplification, methylation detection, and library preparation for next generation sequencing.

NEBsolutions, a dedicated team within the New England Biolabs framework, comprises 110 PhDs, more than half with greater than 10 years of tenure at New England Biolabs. They provide the highest level of support to meet the specific needs of New England Biolabs' OEM and customized product customers. The NEBsolutions team excels at meeting aggressive timelines and offers rapid lead-times. This includes leveraging the capabilities of the entire company to help customers achieve their goals. The NEBsolutions team will work to optimize reagent formulation, function, and manufacturing process, resulting in an optimized product while minimizing cost.

"New England Biolabs has been supplying high-quality reagents to the molecular diagnostics community since 1995," said John Pelletier, director of NEBsolutions. "Through the NEBsolutions team, you gain access to NEB’s broad array of resources, including the deep scientific know-how to functionally optimize your product, comprehensive experience in the manufacturing of high-quality products, and extensive experience in supply chain management and risk mitigation. Our quality-by-design approach ensures product performance and consistency that surpass customer needs."

Related Links:
New England Biolabs
NEBsolutions



Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.